| Company type | Public |
|---|---|
|
| |
| Industry | Biotechnology |
| Founded | 1987; 37 years ago (1987) |
| Founder | Michael Wall |
| Headquarters | , |
Key people | Richard Pops (CEO) |
| Revenue |  US$1.1 billion (2022)[2] |
 US$-20.5 million | |
| US$-158 million (2022) | |
| Total assets | US$1.9 billion |
| Total equity | US$1 billion |
Number of employees | 2,100 |
| Website | www.alkermes.com |
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall.[3] In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc.[4] The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and manufacturing facilities in Athlone, Ireland, and Wilmington, Ohio.[1]
Alkermes has four proprietary commercial drug products[5] approved for the treatment of schizophrenia, bipolar I disorder, alcohol dependence and opioid dependence. These include olanzapine and samidorphan (Lybalvi), an atypical antipsychotic and opioid modulator combination intended for the treatment of schizophrenia and bipolar I disorder; aripiprazole lauroxil (Aristada), a long-acting injectable for schizophrenia; and naltrexone for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence.
Other products utilizing Alkermes' proprietary technologies include: diroximel fumarate (Vumerity) for multiple sclerosis, risperidone (microspheres) long-acting injectable (Risperdal Consta) for schizophrenia and bipolar I disorder, paliperidone palmitate (Invega Sustenna, Invega Trinza and Invega Hafyerain in the U.S., Xeplion, Trevicta and Bynnali in Europe) for schizophrenia.[6][7]
In October 2023, Alkermes announced its first data related to its orexin 2 receptor (OXR2) agonist, ALKS 2680. ALKS 2680 is in development for the treatment of narcolepsy.[8]
In November 2023, Alkermes completed the planned separation of its oncology business into a new company, Mural Oncology, which plans to continue to work on the investigational interleukin-2 (IL-2) drug, nemvaleukin alfa.[9]
